Clinical Trials Browser

Completed × Disease Progression × Gynecologic × Clear all

Urinary Bladder Neoplasms, Bone Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Melanoma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Disease Progression, Triple Negative Breast Neoplasms

NCT00339651 2020-08-14

Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer

Completed

745 enrolled

Gynecologic

Endometrial Hyperplasia, Hyperplasia, Uterine Hemorrhage, Endometrial Neoplasms, Disease Progression

NCT03804866 2019-01-15

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

Phase 2 Completed

14 enrolled

Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

NCT01358071 2018-09-27

NGR018

Phase 2 Completed

119 enrolled

Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

NCT02522585 2016-04-20

p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management

Completed

100 enrolled

Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Disease Progression

NCT00517621 2011-02-25

Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire

Phase 2 Completed

100 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Disease Progression

Clinical Trials

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

NGR018

p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management

Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire